Cargando…
In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients
BACKGROUND: In osteosarcoma (OS) and most Ewing sarcoma (EWS) patients, the primary tumor originates in the bone. Although tumor resection surgery is commonly used to treat these diseases, it frequently leaves massive bone defects that are particularly difficult to be treated. Due to the therapeutic...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022272/ https://www.ncbi.nlm.nih.gov/pubmed/24716831 http://dx.doi.org/10.1186/1479-5876-12-95 |
_version_ | 1782316374815670272 |
---|---|
author | Lucarelli, Enrico Bellotti, Chiara Mantelli, Melissa Avanzini, Maria Antonietta Maccario, Rita Novara, Francesca Arrigo, Giulia Zuffardi, Orsetta Zuntini, Monia Pandolfi, Martina Sangiorgi, Luca Lisini, Daniela Donati, Davide Duchi, Serena |
author_facet | Lucarelli, Enrico Bellotti, Chiara Mantelli, Melissa Avanzini, Maria Antonietta Maccario, Rita Novara, Francesca Arrigo, Giulia Zuffardi, Orsetta Zuntini, Monia Pandolfi, Martina Sangiorgi, Luca Lisini, Daniela Donati, Davide Duchi, Serena |
author_sort | Lucarelli, Enrico |
collection | PubMed |
description | BACKGROUND: In osteosarcoma (OS) and most Ewing sarcoma (EWS) patients, the primary tumor originates in the bone. Although tumor resection surgery is commonly used to treat these diseases, it frequently leaves massive bone defects that are particularly difficult to be treated. Due to the therapeutic potential of mesenchymal stem cells (MSCs), OS and EWS patients could benefit from an autologous MSCs-based bone reconstruction. However, safety concerns regarding the in vitro expansion of bone marrow-derived MSCs have been raised. To investigate the possible oncogenic potential of MSCs from OS or EWS patients (MSC-SAR) after expansion, this study focused on a biosafety assessment of MSC-SAR obtained after short- and long-term cultivation compared with MSCs from healthy donors (MSC-CTRL). METHODS: We initially characterized the morphology, immunophenotype, and differentiation multipotency of isolated MSC-SAR. MSC-SAR and MSC-CTRL were subsequently expanded under identical culture conditions. Cells at the early (P3/P4) and late (P10) passages were collected for the in vitro analyses including: sequencing of genes frequently mutated in OS and EWS, evaluation of telomerase activity, assessment of the gene expression profile and activity of major cancer pathways, cytogenetic analysis on synchronous MSCs, and molecular karyotyping using a comparative genomic hybridization (CGH) array. RESULTS: MSC-SAR displayed comparable morphology, immunophenotype, proliferation rate, differentiation potential, and telomerase activity to MSC-CTRL. Both cell types displayed signs of senescence in the late stages of culture with no relevant changes in cancer gene expression. However, cytogenetic analysis detected chromosomal anomalies in the early and late stages of MSC-SAR and MSC-CTRL after culture. CONCLUSIONS: Our results demonstrated that the in vitro expansion of MSCs does not influence or favor malignant transformation since MSC-SAR were not more prone than MSC-CTRL to deleterious changes during culture. However, the presence of chromosomal aberrations supports rigorous phenotypic, functional and genetic evaluation of the biosafety of MSCs, which is important for clinical applications. |
format | Online Article Text |
id | pubmed-4022272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40222722014-05-16 In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients Lucarelli, Enrico Bellotti, Chiara Mantelli, Melissa Avanzini, Maria Antonietta Maccario, Rita Novara, Francesca Arrigo, Giulia Zuffardi, Orsetta Zuntini, Monia Pandolfi, Martina Sangiorgi, Luca Lisini, Daniela Donati, Davide Duchi, Serena J Transl Med Research BACKGROUND: In osteosarcoma (OS) and most Ewing sarcoma (EWS) patients, the primary tumor originates in the bone. Although tumor resection surgery is commonly used to treat these diseases, it frequently leaves massive bone defects that are particularly difficult to be treated. Due to the therapeutic potential of mesenchymal stem cells (MSCs), OS and EWS patients could benefit from an autologous MSCs-based bone reconstruction. However, safety concerns regarding the in vitro expansion of bone marrow-derived MSCs have been raised. To investigate the possible oncogenic potential of MSCs from OS or EWS patients (MSC-SAR) after expansion, this study focused on a biosafety assessment of MSC-SAR obtained after short- and long-term cultivation compared with MSCs from healthy donors (MSC-CTRL). METHODS: We initially characterized the morphology, immunophenotype, and differentiation multipotency of isolated MSC-SAR. MSC-SAR and MSC-CTRL were subsequently expanded under identical culture conditions. Cells at the early (P3/P4) and late (P10) passages were collected for the in vitro analyses including: sequencing of genes frequently mutated in OS and EWS, evaluation of telomerase activity, assessment of the gene expression profile and activity of major cancer pathways, cytogenetic analysis on synchronous MSCs, and molecular karyotyping using a comparative genomic hybridization (CGH) array. RESULTS: MSC-SAR displayed comparable morphology, immunophenotype, proliferation rate, differentiation potential, and telomerase activity to MSC-CTRL. Both cell types displayed signs of senescence in the late stages of culture with no relevant changes in cancer gene expression. However, cytogenetic analysis detected chromosomal anomalies in the early and late stages of MSC-SAR and MSC-CTRL after culture. CONCLUSIONS: Our results demonstrated that the in vitro expansion of MSCs does not influence or favor malignant transformation since MSC-SAR were not more prone than MSC-CTRL to deleterious changes during culture. However, the presence of chromosomal aberrations supports rigorous phenotypic, functional and genetic evaluation of the biosafety of MSCs, which is important for clinical applications. BioMed Central 2014-04-09 /pmc/articles/PMC4022272/ /pubmed/24716831 http://dx.doi.org/10.1186/1479-5876-12-95 Text en Copyright © 2014 Lucarelli et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Lucarelli, Enrico Bellotti, Chiara Mantelli, Melissa Avanzini, Maria Antonietta Maccario, Rita Novara, Francesca Arrigo, Giulia Zuffardi, Orsetta Zuntini, Monia Pandolfi, Martina Sangiorgi, Luca Lisini, Daniela Donati, Davide Duchi, Serena In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients |
title | In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients |
title_full | In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients |
title_fullStr | In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients |
title_full_unstemmed | In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients |
title_short | In vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients |
title_sort | in vitro biosafety profile evaluation of multipotent mesenchymal stem cells derived from the bone marrow of sarcoma patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022272/ https://www.ncbi.nlm.nih.gov/pubmed/24716831 http://dx.doi.org/10.1186/1479-5876-12-95 |
work_keys_str_mv | AT lucarellienrico invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT bellottichiara invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT mantellimelissa invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT avanzinimariaantonietta invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT maccariorita invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT novarafrancesca invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT arrigogiulia invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT zuffardiorsetta invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT zuntinimonia invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT pandolfimartina invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT sangiorgiluca invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT lisinidaniela invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT donatidavide invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients AT duchiserena invitrobiosafetyprofileevaluationofmultipotentmesenchymalstemcellsderivedfromthebonemarrowofsarcomapatients |